Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2020 | NeoTRIPaPDL1: dynamics of TILs & PD-L1 expression in breast cancer

Giampaolo Bianchini, MD, of IRCCS San Raffaele Hospital, Milan, Italy, discusses data coming from the NeoTRIPaPDL1 trial (NCT02620280) – a randomized Phase III study evaluating neoadjuvant atezolizumab with carboplatin and nab-paclitaxel in patients with early high-risk and locally advanced triple negative breast cancer. The data presented at ESMO 2020 looked at the role of tumour infiltrating lymphocytes (TILs) and PD-L1 expression in samples collected at baseline, Day 1 of cycle 2 or at surgery. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.